Laboratory safety of dupilumab in patients aged 6–11 years with severe atopic dermatitis : results from a phase III clinical trial by Paller, A.S. et al.
This is a repository copy of Laboratory safety of dupilumab in patients aged 6–11 years 
with severe atopic dermatitis : results from a phase III clinical trial.




Paller, A.S., Wollenberg, A., Siegfried, E. et al. (12 more authors) (2021) Laboratory safety 
of dupilumab in patients aged 6–11 years with severe atopic dermatitis : results from a 





This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) 
licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new 
works must also acknowledge the authors and be non-commercial. You don’t have to license any derivative 
works on the same terms. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Vol.:(0123456789)
Pediatric Drugs (2021) 23:515–527 
https://doi.org/10.1007/s40272-021-00459-x
ORIGINAL RESEARCH ARTICLE
Laboratory Safety of Dupilumab in Patients Aged 6–11 Years 
with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial
Amy S. Paller1 · Andreas Wollenberg2 · Elaine Siegfried3 · Diamant Thaçi4 · Michael J. Cork5 · Peter D. Arkwright6 · 
Melinda Gooderham7,8 · Xian Sun9 · John T. O’Malley10 · Faisal A. Khokhar9 · Jignesh Vakil11 · Ashish Bansal9 · 
Karli Rosner12 · Brad Shumel9 · Noah A. Levit9 
Accepted: 23 June 2021 / Published online: 31 August 2021 
© The Author(s) 2021
Abstract
Background Previous studies of dupilumab in adolescents and adults with moderate-to-severe atopic dermatitis (AD) showed 
no clinically meaningful adverse changes in laboratory parameters.
Objective The aim of this study was to assess laboratory outcomes in children aged 6–11 years with severe AD in a rand-
omized, placebo-controlled, phase III trial of dupilumab.
Methods Children aged 6–11 years with severe AD were randomized 1:1:1 to 16 weeks of dupilumab 300 mg every 4 weeks, 
100 or 200 mg every 2 weeks, or matching placebo, all with concomitant topical corticosteroids (TCS). Blood samples were 
collected at baseline and Weeks 4, 8, and 16; urine samples were collected at baseline and Weeks 4 and 16.
Results Of 367 patients enrolled in the study, 362 were included in the safety analysis, 351 completed study treatment, and 4 
withdrew due to treatment-emergent adverse events not related to laboratory abnormalities. Both dupilumab + TCS groups 
showed overall trends toward increases in mean blood levels of eosinophils and alkaline phosphatase, and decreases in mean 
blood levels of platelets, neutrophils, and lactate dehydrogenase levels, without corresponding mean changes in the placebo + 
TCS group. None of these changes were associated with symptoms or clinically meaningful adverse outcomes, and none led 
to treatment modification. No clinically significant changes or trends were observed for other measured laboratory parameters.
Conclusion There were no clinically meaningful adverse changes in routine laboratory parameters attributable to treatment 
with dupilumab + TCS. Changes in platelet counts and lactate dehydrogenase levels likely reflect reduced inflammation. 
These results confirm similar findings in adults and adolescents, and suggest that there is no need for routine laboratory 
monitoring of children aged 6–11 years treated with dupilumab + TCS for severe AD.
Trial Registration ClinicalTrials.gov Identifier: NCT03345914.
Digital Features for this article can be found at https:// doi. org/ 10. 
6084/ m9. figsh are. 14825 760.
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Key Points 
Baseline and follow-up laboratory tests are required for 
patients with atopic dermatitis (AD) treated with sys-
temic immunosuppressants.
Previous studies of dupilumab (a monoclonal antibody 
that specifically inhibits signaling of interleukin-4 and 
interleukin-13) in adolescents and adults with moderate-
to-severe AD demonstrated no changes in laboratory 
parameters necessitating modification of treatment.
This randomized, placebo-controlled, phase III clinical 
trial of dupilumab with concomitant topical corticosteroids 
(TCS) for children aged 6–11 years with severe AD also 
demonstrated no significant changes in laboratory param-
eters, supporting the use of dupilumab + TCS without 
routine laboratory monitoring in patients aged ≥ 6 years.
2  Methods
2.1  Study Design, Patients, and Treatment
LIBERTY AD PEDS (ClinicalTrials.gov Identifier: 
NCT03345914) was a randomized, double-blinded, 
placebo-controlled phase III clinical trial [15]. Details 
of the study design and patient enrollment criteria have 
been previously published [15]. In brief, patients were 
aged 6–11 years with severe AD [18] inadequately con-
trolled with topical AD medications. Study participants 
underwent a screening/washout period that lasted up to 
9 weeks and a 2-week TCS standardization period, after 
which they were randomized 1:1:1 to receive subcutane-
ous dupilumab 300 mg every 4 weeks (q4w); dupilumab 
every 2 weeks (q2w) at a dose of either 100  mg (if 
baseline weight < 30 kg) or 200 mg (if baseline weight 
≥ 30 kg); or matching placebo. All groups received con-
comitant medium-potency TCS (or low-potency TCS 
on skin where continuous treatment with medium-
potency TCS was considered unsafe). Treatment con-
tinued for 16 weeks, followed by a 12-week follow-up 
period or enrollment in an open-label extension study 
(LIBERTY AD PED-OLE; ClinicalTrials.gov Identi-
fier: NCT02612454) [14]. Patients eligible for LIB-
ERTY AD PEDS had an Investigator’s Global Assess-
ment score of 4 (on a scale of 0–4), an Eczema Area 
and Severity Index ≥ 21, a Pruritus Numerical Rating 
Scale score ≥ 4, and body surface area affected ≥ 15%. 
Patients were excluded from the trial if they were on 
current treatment for hepatic disease or had evidence 
of liver disease as indicated by persistent (confirmed 
by repeated tests ≥ 2 weeks apart) elevated transami-
nases (alanine aminotransferase [ALT] and/or aspartate 
aminotransferase [AST]) > 3 times the upper limit of 
normal (ULN) during the screening period; or had any 
of the following laboratory abnormalities at screening: 
platelet count ≤ 100 ×  103/μL, neutrophil count < 1.5 × 
 103/μL, creatine phosphokinase (CPK) > 5 × ULN, or 
serum creatinine > 1.5 × ULN.
2.2  Ethics
The study was conducted following the ethical principles 
derived from the Declaration of Helsinki, the International 
Council for Harmonisation guidelines, Good Clinical Prac-
tice guideline, and local applicable regulatory require-
ments. Written informed consent was obtained from all 
patients and the patients’ parents/guardians prior to com-
mencement of any study treatment.
1 Introduction
For children with severe atopic dermatitis (AD), use of sys-
temic corticosteroids and other immunosuppressive thera-
pies is associated with safety risks [1–3]. Standard-of-care 
use of these drugs requires baseline and follow-up labora-
tory tests to monitor for evidence of myelosuppression, lipid 
abnormalities, and/or organ toxicity [4]. The need for serial 
venipuncture with such therapies may have significant toler-
ability implications in children, particularly when access to 
dedicated pediatric phlebotomy is not available [5].
Dupilumab is a fully human  VelocImmune®-derived [6, 7] 
monoclonal antibody that blocks the shared receptor compo-
nent for interleukin (IL)-4 and IL-13, thus inhibiting signaling 
of both IL-4 and IL-13, which are key and central drivers of 
type 2 inflammatory diseases [8]. Clinical trials of dupilumab 
with or without topical corticosteroids (TCS) in adults and ado-
lescents with moderate-to-severe AD and in children aged 6–11 
years with severe AD have shown significant improvement in 
signs and symptoms of AD and patient quality of life with 
dupilumab treatment, with an acceptable safety profile [9–15]. 
No clinically significant adverse changes in laboratory param-
eters in adults and adolescents were attributable to dupilumab, 
supporting its use for treatment of moderate-to-severe AD with-
out routine laboratory monitoring [16, 17]. To characterize the 
impact of dupilumab on laboratory findings in children, we ana-
lyzed the laboratory safety data from a phase III clinical trial 
conducted in children aged 6–11 years with severe AD [15].
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2.3  Laboratory Assessment
Blood samples were collected for laboratory assessment at 
baseline and Weeks 4, 8, and 16, and urine samples were 
collected at baseline and Weeks 4 and 16; samples were 
analyzed by two central laboratories (PPD Global Central 
Labs LLC, Highland Heights, KY, USA; and PPD Global 
Central Lab BVBA, Zaventem, Belgium). The laboratory 
parameters that were assessed are shown in Supplemental 
Table S1 (see electronic supplementary material [ESM]), 
and include hematologic (red blood cell, platelet, and 
white blood cell), serum chemistry (metabolic, electrolyte, 
renal, liver, and lipid), and urinalysis parameters.
In cases of significantly abnormal laboratory values, as 
determined by the study investigator, the test was repeated, 
and ancillary investigations were performed as needed. 
Abnormal laboratory findings were reported as a treatment-
emergent adverse event (TEAE) based on the following 
criteria, as determined by study investigators: if findings 
were accompanied by symptoms, and/or required additional 
diagnostic testing or medical/surgical intervention, and/or 
led to a change in dosing (outside of protocol-stipulated 
dose adjustments, patient withdrawal from the study, or 
significant additional concomitant drug treatment or other 
therapy).
Temporary discontinuation of study treatment was 
required for patients who developed the following labora-
tory abnormalities: AST and/or ALT values > 3 × ULN but 
≤ 5 × ULN; neutrophil count < 1.5 ×  103/μL but > 0.5 ×  103/
μL; platelet count ≤ 100 ×  103/μL but > 50 ×  103/μL; CPK 
> 5 × ULN; serum creatinine > 1.5 × ULN; or eosinophil 
count > 5000/μL. Treatment was permanently discontinued 
in patients with neutrophil count ≤ 0.5 ×  103/μL; platelet 
count ≤ 50 ×  103/μL; ALT and/or AST > 3 × ULN with total 
bilirubin > 2 × ULN (unless elevated bilirubin is related to 
confirmed Gilbert’s syndrome); or confirmed AST and/or 
ALT > 5 × ULN for >2 weeks.
2.4  Statistical Analysis
This analysis was based on all randomized patients who 
received one or more dose of study drug, as treated (i.e., the 
safety analysis set). All statistics are descriptive and com-
puted based on the number of available samples at each time 
point; no imputation for missing values was used. Analyses 
included baseline value, median values at each time point, 
and change from baseline at each time point reported as 
mean with standard deviation. The number and proportion 
of patients with one or more laboratory abnormality that was 
reported as a TEAE during the 16-week treatment period 
was also assessed. TEAEs are presented as Medical Diction-
ary for Regulatory Activities Preferred Terms (MedDRA 
PTs). TEAEs were classified as mild, moderate, and severe, 
per clinician’s assessment (Supplemental Methods, see 
ESM). In addition, the proportion of patients whose values 
for platelets, eosinophils, neutrophils, and lactate dehydro-
genase (LDH) shifted between low, normal, and high by visit 
(baseline and Weeks 4, 8, and 16) were assessed. Finally, 
the proportions of patients in each grade of severity for key 
outcomes (red blood cell parameters, platelets, eosinophils, 
neutrophils, alkaline phosphatase [ALP], bilirubin, ALT, 
AST, creatinine, and potassium) were evaluated, regardless 
of whether the outcomes were reported as TEAEs. Grades 
(defined as Grade 1 = mild, Grade 2 = moderate, Grade 
3 = severe or medically significant [but not immediately 
life-threatening], and Grade 4 = potentially life-threaten-
ing) were based on the Common Terminology Criteria for 
Adverse Events (CTCAE); Version 5.0 [19], except for 
eosinophilia, for which grades were defined according to 
the Nordic study group on myeloproliferative disorders [20].
3  Results
3.1  Patients
A total of 367 patients were enrolled in the study, and 362 
were included in the safety analysis set. Five patients (2 in 
the placebo + TCS group, 2 in the dupilumab 300 mg q4w + 
TCS group, and 1 in the dupilumab 100/200 mg q2w + TCS 
group) were randomized but did not receive study treatment 
and were therefore excluded from the safety analysis set.
Overall, 96% of patients completed the study. No 
patients withdrew from the study due to laboratory abnor-
malities, and no patients temporarily or permanently dis-
continued study treatment due to laboratory abnormalities. 
Two patients in the placebo + TCS group reported TEAEs 
(1 each of asthma, and AD) unrelated to laboratory param-
eters that led to permanent dose discontinuation, as did two 
in the dupilumab 100/200 mg q2w + TCS group (1 each 
of food allergy and bacterial conjunctivitis). The propor-
tion of patients with one or more laboratory abnormali-
ties reported as TEAEs was low (1.7%, 0.8%, and 2.5% in 
patients treated with placebo + TCS, dupilumab 300 mg 
q4w + TCS, and dupilumab 100/200 mg q2w + TCS, 
respectively; Table 1).
3.2  Red Blood Cells and Platelets
No clinically significant changes from baseline and no 
consequential differences between treatment groups were 
observed during the 16-week treatment period for hemo-
globin level and platelet count (Fig. 1a, b) or other red blood 
cell parameters (Supplemental Table S2a–c, see ESM), 
although there was a trend toward decreasing platelet counts 
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in both dupilumab + TCS groups over 16 weeks (Fig. 1b; 
Supplemental Fig. S1, see ESM). There were no clinically 
meaningful differences between treatment groups in shifts 
from baseline levels of platelets (Table 2). No patients 
reported TEAEs related to red blood cells, and none had 
Grade 3 anemia (Supplemental Table S2c, see ESM) or other 
abnormalities in red blood cell parameters (data not shown).
One patient in the dupilumab 300 mg q4w + TCS 
group reported an isolated drop in platelet count that 
met the criteria for Grade 3 thrombocytopenia (change 
from baseline − 245 ×  109/L) at Week 8; platelet count 
reverted to normal by Week 16 without modification in 
therapy (change from baseline: − 6 ×  109/L; Supplemen-
tal Table S2b, Supplemental Fig. S2, see ESM); this was 
not reported as a TEAE. Thrombocytopenia was reported 
as a TEAE in one patient in the dupilumab 100 mg q2w 
+ TCS group; this patient had a normal platelet count 
at baseline (273 ×  109/L; age-adjusted normal range 
130–382 ×  109/L) that decreased to 56 ×  109/L at Week 
8 and normalized by Week 10 (226 ×  109/L; Table 1). 
There were no bleeding or bruising abnormalities 
reported in patients who had decreased platelet count 
recorded either as a TEAE or meeting the criteria for 
Grade 3 thrombocytopenia. Moderate thrombocytosis 
was reported as a TEAE in one patient in the dupilumab 
300 mg q4w + TCS group; the patient had a baseline 
platelet count of 442 ×  109/L that increased to 747 × 
 109/L at Week 8 (age-adjusted normal range 130–382 × 
 109/L) and decreased by Week 16 to near baseline values 
(416 ×  109/L; Table 1).
3.3  White Blood Cells
Summary statistics for white blood cell parameters are pre-
sented in Supplemental Table S3a (see ESM). No clinically 
Table 1  Laboratory abnormalities reported as TEAEs
This table includes all TEAEs reported by investigators that were PTs related to laboratory assessments in the listed SOCs
MedDRA Medical Dictionary for Regulatory Activities, n total number of patients in the treatment group, PT MedDRA Preferred Term, q2w 
every 2 weeks, q4w every 4 weeks, SOC MedDRA System Organ Class, TCS topical corticosteroid, TEAE treatment-emergent adverse event
a The patient had an elevated eosinophil count at baseline (4.3 ×  109/L) that increased to 7.8 ×  109/L at Week 4 (age-adjusted normal range 
0–0.5 ×  109/L); the eosinophil count decreased to 5.3 ×  109/L at Week 8. This TEAE was classified as moderate in intensity, was not considered 
related to study drug, and did not require any treatment or withdrawal of study drug
b The patient had a normal platelet count at baseline (273 ×  109/L) that decreased to 56 ×  109/L at Week 8 (age-adjusted normal range 130–382 
×  109/L); the platelet count normalized by Week 10 to 226 ×  109/L. This TEAE was classified as moderate in intensity, was considered related to 
study drug, and did not require any treatment or withdrawal of study drug
c The patient had a baseline platelet count of 442 ×  109/L that increased to 747 ×  109/L at Week 8 (age-adjusted normal range 130–382 ×  109/L); 
the platelet count decreased by Week 10 to 416 ×  109/L. This TEAE was classified as moderate in intensity, was considered related to study 
drug, and did not require any treatment or withdrawal of study drug
d The patient had a normal blood potassium level at baseline (4.3 mmol/L) that increased to 6.1 mmol/L at Week 8 (age-adjusted normal range 
2.8–6.3 mmol/L); the potassium level normalized by Week 12 to 4.8 mmol/L. This TEAE was classified as mild in intensity, was not considered 
related to study drug, and did not require any treatment or withdrawal of study drug
e The patient had no proteinuria at baseline (0 mg/dL); proteinuria was detected at a level of 30 mg/dL at Week 4, and protein levels returned to 
baseline by Week 8 to 0 mg/dL. This TEAE was classified as mild in intensity, was not considered related to study drug, and did not require any 
treatment or withdrawal of study drug
f The patient had an isolated elevated baseline proteinuria (30 mg/dL) that increased to 100 mg/dL at Week 4; protein levels normalized to 0 mg/
dL by Week 16. This TEAE was classified as mild in intensity, was not considered related to study drug, and did not require any treatment or with-
drawal of study drug
TEAEs by MedDRA SOC and PT, n (%) Placebo + TCS
(n = 120)
Dupilumab 
300 mg q4w + TCS
(n = 120)
Dupilumab 
100/200 mg q2w + TCS
(n = 122)
Patients with ≥ 1 laboratory abnormality reported as 
TEAE
2 (1.7) 1 (0.8) 3 (2.5)
Blood and lymphatic system disorders (SOC)
 Eosinophilia (PT) 0 0 1 (0.8)a
 Thrombocytopenia (PT) 0 0 1 (0.8)b
 Thrombocytosis (PT) 0 1 (0.8)c 0
Investigations (SOC)
 Blood potassium increased (PT) 1 (0.8)d 0 0
Renal and urinary disorders (SOC)

























Fig. 1  Mean change from baseline over time in a hemoglobin level, b platelet count, c leukocyte count, d neutrophil count, e eosinophil count, and f absolute eosinophil levels. White horizontal 
lines indicate medians. X depicts mean values. Top and bottom of each box represents Q3 and Q2, respectively. Upper and lower vertical bars represent Q4 and Q1, respectively; horizontal seg-
ments on each end of the vertical bars represent minimum and maximum values. Red dashed line represents upper limit of normal (0.5 ×  109/L). n1 number of patients with evaluation level at 
visit, Q quartile, q2w every 2 weeks, q4w every 4 weeks, SD standard deviation, TCS topical corticosteroid. aNumber of patients with a value for change from baseline. bNumber of patients with 
a value for absolute count
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significant changes from baseline and no meaningful dif-
ferences between treatment groups were observed in mean 
counts for leukocytes, neutrophils, or most other white blood 
cell parameters in any treatment group (Fig. 1c, d; Supple-
mental Table S3a, see ESM).
Eosinophil counts at baseline were elevated above the 
normal range in all treatment groups (Fig. 1e, f; Supplemen-
tal Table S3a, see ESM). Mean eosinophil counts increased 
over time from baseline, peaking at Week 8 in the dupilumab 
300 mg q4w + TCS and placebo + TCS groups, and increas-
ing to Week 16 in the dupilumab 100/200 mg q2w + TCS 
group (Fig. 1e, f). The mean changes from baseline to Week 
16 were 0.10 ×  109/L and 0.25 ×  109/L in the dupilumab 
300 mg q4w + TCS and dupilumab 100/200 mg q2w + TCS 
groups, respectively, compared with −0.01 ×  109/L in the 
placebo group (Supplemental Table S3a, see ESM). In con-
trast, median eosinophil counts showed little variation over 
time (median counts, range: placebo + TCS, 0.7–0.8 ×  109/L; 
dupilumab 300 mg q4w + TCS, 0.7–0.8 ×  109/L; dupilumab 
100/200 mg q2w + TCS, 0.6–0.8 ×  109/L; Fig. 1f; Supple-
mental Table S3a, see ESM). Similar proportions of patients 
in each treatment group shifted from high eosinophil counts 
at baseline to normal counts at Week 16 (Table 3).
Grade 3 eosinophilia (i.e., > 5.00 ×  109/L, severe) was 
reported at one or more post-baseline time points for five, 
two, and one patient(s) in the dupilumab 300 mg q4w + 
TCS, 100/200 mg q2w + TCS, and placebo + TCS groups, 
respectively; no patients had Grade 3 eosinophilia at base-
line (Table 4). Eosinophil counts declined after the Grade 
3 events for four of the seven dupilumab + TCS-treated 
patients and the placebo + TCS-treated patient; for the 
remaining three dupilumab + TCS-treated patients, Grade 
3 eosinophilia was first reported at Week 16 (Supplemental 
Fig. S3, see ESM). No symptoms were associated with any 
of the Grade 3 eosinophilia events. All eight patients with 
Grade 3 eosinophilia had a history of other type 2 inflam-
matory disorders, including asthma, allergic rhinitis, chronic 
rhinosinusitis, food or other allergies, allergic conjunctivitis, 
and hives (Supplemental Fig. S3, see ESM), and all had 
previously used systemic non-steroidal immunosuppressant 
therapies for AD. In addition, four of the patients with Grade 
3 eosinophilia had TEAEs of type 2 inflammatory disorders 
(MedDRA PTs) as follows: moderate eosinophilia and mild 
allergic rhinitis (1 patient, dupilumab 100 mg q2w + TCS 
[note: the TEAE of moderate eosinophilia coincided with 
the event of Grade 3 eosinophilia; see in the following]); 
mild asthma and mild urticaria (1 patient, dupilumab 300 mg 
q4w + TCS); moderate allergic conjunctivitis and moderate 
atopy (1 patient, dupilumab 300 mg q4w + TCS); and severe 
AD (1 patient [2 events], placebo + TCS) (Supplemental 
Fig. S3, see ESM). For the patient in the dupilumab 100 mg 
q2w + TCS group with both a TEAE of moderate eosino-
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elevated at baseline (4.3 ×  109/L; age-adjusted normal range, 
0–0.5 ×  109/L), increasing to 7.8 ×  109/L at Week 4 (Grade 
3, > 5.0 ×  109/L) and decreasing to 5.3 ×  109/L at Week 8 
and 5.5 ×  109/L at Week 16 (Table 1; Supplemental Fig. 
S3, see ESM [patient 1]). The other seven patients did not 
report any TEAEs during the period when they had Grade 3 
eosinophilia. In addition, none of the patients with Grade 3 
eosinophilia had any findings suggestive of gastrointestinal 
disorders, vasculitis, or other adverse events associated with 
autoimmune conditions, and none had known helminthic 
infections.
No clinically meaningful adverse changes from base-
line and no meaningful differences between treatment 
groups were observed in neutrophil counts, although both 
dupilumab + TCS groups showed a trend to decrease in 
mean neutrophil counts from baseline to Week 16 (Fig. 1d; 
Supplemental Table S3a, see ESM). Compared with pla-
cebo + TCS, a numerically higher proportion of patients 
in the dupilumab 300 mg q4w + TCS group, but not the 
dupilumab 100/200 mg q2w + TCS group, shifted from nor-
mal levels of neutrophils at baseline to low levels at Week 16 
(Table 5). Three patients had Grade 3 neutropenia at baseline 
Table 2  Shift from baseline: platelets (×  109/L)
Normal range: age 1–6 years: male, 197–382 ×  109/L; female, 213–363 ×  109/L; age 7–12 years: male, 175–311 ×  109/L; female, 130–314 × 
 109/L
n total number of patients in the treatment group, n1 number of patients with evaluation level (low, normal, high) at visit, N2 number of patients 
with baseline status, q2w every 2 weeks, q4w every 4 weeks, TCS topical corticosteroid





300 mg q4w + TCS
(n = 120)
Dupilumab 
100/200 mg q2w + TCS
(n = 122)
Baseline status
Low Normal High Low Normal High Low Normal High
4 Low 0/1 1/65 (1.5) 0/41 1/2 (50.0) 0/53 0/44 0/0 1/57 (1.8) 0/48
Normal 1/1 (100) 48/65 (73.8) 4/41 (9.8) 1/2 (50.0) 43/53 (81.1) 13/44 (29.5) 0/0 47/57 (82.5) 14/48 (29.2)
High 0/1 16/65 (24.6) 37/41 (90.2) 0/2 10/53 (18.9) 31/44 (70.5) 0/0 9/57 (15.8) 34/48 (70.8)
8 Low 0/1 0/61 0/44 0/4 1/53 (1.9) 0/40 0/0 2/55 (3.6) 0/46
Normal 1/1 (100) 45/61 (73.8) 8/44 (18.2) 3/4 (75.0) 44/53 (83.0) 17/40 (42.5) 0/0 44/55 (80.0) 14/46 (30.4)
High 0/1 16/61 (26.2) 36/44 (81.8) 1/4 (25.0) 8/53 (15.1) 23/40 (57.5) 0/0 9/55 (16.4) 32/46 (69.6)
16 Low 1/2 (50) 1/59 (1.7) 0/45 1/4 (25.0) 2/61 (3.3) 0/42 0/0 2/59 (3.4) 1/47 (2.1)
Normal 1/2 (50) 46/59 (78.0) 9/45 (20.0) 2/4 (50.0) 55/61 (90.2) 15/42 (35.7) 0/0 47/59 (79.7) 15/47 (31.9)
High 0/2 12/59 (20.3) 36/45 (80.0) 1/4 (25.0) 4/61 (6.6) 27/42 (64.3) 0/0 10/59 (16.9) 31/47 (66.0)
Table 3  Shift from baseline: eosinophils (×  109/L)
Normal range: age 1–6 years, 0–0.6 ×  109/L; age 7–12 years, 0–0.5 ×  109/L
n total number of patients in the treatment group, n1 number of patients with evaluation level (low, normal, high) at visit, N2 number of patients 
with baseline status, q2w every 2 weeks, q4w every 4 weeks, TCS topical corticosteroid
Study week Evaluation 
n1/N2 (%)
Placebo + TCS  
(n = 120)
Dupilumab 300 mg q4w + TCS 
(n = 120)
Dupilumab 100/200 mg q2w + TCS 
(n = 122)
Baseline status
Low Normal High Low Normal High Low Normal High
4 Low 0/0 0/45 0/66 0/0 0/37 0/71 0/0 0/49 0/61
Normal 0/0 33/45 (73.3) 14/66 (21.2) 0/0 34/37 (91.9) 14/71 (19.7) 0/0 37/49 (75.5) 13/61 (21.3)
High 0/0 12/45 (26.7) 52/66 (78.8) 0/0 3/37 (8.1) 57/71 (80.3) 0/0 12/49 (24.5) 48/61 (78.7)
8 Low 0/0 0/45 0/64 0/0 0/39 0/67 0/0 0/49 0/56
Normal 0/0 31/45 (68.9) 9/64 (14.1) 0/0 32/39 (82.1) 14/67 (20.9) 0/0 34/49 (69.4) 11/56 (19.6)
High 0/0 14/45 (31.1) 55/64 (85.9) 0/0 7/39 (17.9) 53/67 (79.1) 0/0 15/49 (30.6) 45/56 (80.4)
16 Low 0/0 0/41 0/65 0/0 0/42 0/71 0/0 0/53 0/61
Normal 0/0 26/41 (63.4) 15/65 (23.1) 0/0 34/42 (81.0) 14/71 (19.7) 0/0 30/53 (56.6) 15/61 (24.6)
High 0/0 15/41 (36.6) 50/65 (76.9) 0/0 8/42 (19.0) 57/71 (80.3) 0/0 23/53 (43.4) 46/61 (75.4)
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(1 patient, dupilumab 300 mg q4w + TCS) or Week 16 (1 
patient, placebo + TCS; 1 patient, dupilumab 200 mg q2w + 
TCS) (Supplemental Table S3b, see ESM); review of labora-
tory reports found no attributable causes for these events.
3.4  Serum Chemistry
No clinically meaningful trends were observed for most 
serum chemistry parameters, including markers of meta-
bolic function, electrolytes, renal function, liver function, 
or lipids, in any treatment group (Supplemental Table S4a–e, 
see ESM).
Mean LDH level decreased from baseline in both 
dupilumab + TCS treatment groups but remained stable in 
the placebo + TCS group (Fig. 2a; Supplemental Table S4d, 
see ESM). More patients in the dupilumab + TCS groups 
than in the placebo + TCS group shifted from high levels 
of LDH at baseline to normal levels at Week 16 (Supple-
mental Table S4f, see ESM). Mean ALP levels increased 
from baseline in both dupilumab + TCS treatment groups 
but not in the placebo + TCS group (Fig. 2b; Supplemental 
Table S4d, see ESM), whereas mean ALT levels remained 
relatively stable in all three treatment groups (Fig. 2c; Sup-
plemental Table S4d, see ESM). No patients had increases 
beyond Grade 2 in ALP, bilirubin, ALT, AST, or creatinine 
(Supplemental Table S5a–e, see ESM). Two patients in the 
placebo + TCS group had transient Grade 3 increases in 
potassium at Week 8 (Supplemental Table S5f, see ESM). 
A mild increase in blood potassium level was reported as a 
TEAE in one patient in the placebo + TCS group; the patient 
had a normal blood potassium level at baseline (4.3 mmol/L) 
that increased to 6.1 mmol/L at Week 8 (age-adjusted nor-
mal range 2.8–6.3 mmol/L) and normalized by Week 12 to 
4.8 mmol/L (Table 1).
3.5  Urinalysis
No clinically meaningful adverse changes in urine param-
eters were observed (Supplemental Table S6, see ESM). 
Two cases of mild proteinuria were reported as TEAEs: one 
each in the placebo + TCS and dupilumab 100 mg q2w + 
TCS groups (Table 1). The patient in the placebo + TCS 
group had no proteinuria at baseline (0 mg/dL), but levels 
increased to 30 mg/dL at Week 4, and then returned to nor-
mal by Week 8 (0 mg/dL). The patient in the dupilumab 
100 mg q2w + TCS group had isolated proteinuria at base-
line (30 mg/dL) that increased to 100 mg/dL at Week 4 and 
normalized by Week 16 (0 mg/dL); Week 8 data were not 
reported for this patient.
Table 4  Proportion of patients with Grade 1–3 eosinophilia, n1/N1 (%)
Patients may have had a grade change at more than one time point
Grades were determined based on Nordic study group on myeloproliferative disorders guidelines for the diagnosis and treatment of eosinophilia. 
2nd version, September 2012 [20]
n total number of patients in the treatment group, n1/N1 number of patients with grade/number of patients with assessment at visit, q2w every 2 
weeks, q4w every 4 weeks, TCS topical corticosteroid








Baseline Grade 1 (Mild): 0.50 ×  109/L–1.50 ×  109/L 68/118 (57.6) 71/119 (59.7) 64/121 (52.9)
Grade 2 (Moderate): > 1.50 ×  109/L–5.00 ×  109/L 14/118 (11.9) 13/119 (10.9) 13/121 (10.7)
Grade 3 (Severe): > 5.00 ×  109/L 0/118 0/119 0/121
Week 4 Grade 1 (Mild): 0.50 ×  109/L–1.50 ×  109/L 72/111 (64.9) 57/109 (52.3) 50/111 (45.0)
Grade 2 (Moderate): > 1.50 ×  109/L–5.00 ×  109/L 6/111 (5.4) 18/109 (16.5) 17/111 (15.3)
Grade 3 (Severe): > 5.00 ×  109/L 1/111 (0.9) 1/109 (0.9) 1/111 (0.9)
Week 8 Grade 1 (Mild): 0.50 ×  109/L–1.50 ×  109/L 67/109 (61.5) 50/107 (46.7) 44/106 (41.5)
Grade 2 (Moderate): > 1.50 ×  109/L–5.00 ×  109/L 15/109 (13.8) 13/107 (12.1) 21/106 (19.8)
Grade 3 (Severe): > 5.00 ×  109/L 1/109 (0.9) 3/107 (2.8) 1/106 (0.9)
Week 16 Grade 1 (Mild): 0.50 ×  109/L–1.50 ×  109/L 63/106 (59.4) 55/114 (48.2) 56/115 (48.7)
Grade 2 (Moderate): > 1.50 ×  109/L–5.00 ×  109/L 14/106 (13.2) 15/114 (13.2) 20/115 (17.4)
Grade 3 (Severe): > 5.00 ×  109/L 0/106 3/114 (2.6) 2/115 (1.7)
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4  Discussion
This analysis confirms that a 16-week course of dupilumab 
+ TCS in children aged 6–11 years with severe AD did not 
lead to any clinically relevant mean changes in laboratory 
parameters requiring treatment modification.
Overall, no clinically meaningful adverse trends were 
found in hematologic parameters. Transient inconsequential 
TEAEs of thrombocytopenia and thrombocytosis (1 patient 
each) were reported in the dupilumab 100 mg q2w + TCS 
and 300 mg q4w + TCS groups, respectively; review of 
laboratory reports found no attributable cause for either of 
these TEAEs, such as concurrent viral illness, medication 
use, or confirmed spurious reporting, all of which are com-
mon causes of isolated laboratory value aberrations. One 
patient in the dupilumab 300 mg q4w + TCS group with 
a normal platelet count at baseline had a small reduction 
in platelet count that normalized without modification in 
therapy by Week 12. Mean platelet counts decreased, but 
remained within normal range, in both dupilumab + TCS 
groups, most likely reflecting diminished acute phase reac-
tant activity linked to AD severity [21, 22]. Similar trends 
were seen in previous studies in adults [16] and adolescents 
[17], also without adverse clinical implications. AD is a 
chronic inflammatory condition with a dynamic course char-
acterized by recurrent acute exacerbations, which can cause 
oscillating levels of acute phase reactants along with chronic 
elevations of systemic markers of inflammation [21–24].
No trends were observed in most white blood cell param-
eters, including mean change from baseline in basophils, 
lymphocytes, monocytes, and leukocytes. There was a trend 
for a decrease in mean neutrophil counts and a trend for 
an increase in the number of patients in the dupilumab + 
TCS groups having Grades 1 and 2 neutropenia at Week 16. 
Mild increases in mean eosinophil counts were observed in 
all treatment groups during the treatment period, consist-
ent with previous reports evaluating dupilumab in adults 
and adolescents with moderate-to-severe AD [9, 16, 17], 
asthma [25, 26], and chronic rhinosinusitis with nasal pol-
yps [27]. For the placebo and dupilumab q4w groups, these 
changes were transient, peaking at Week 8 and returning 
to near baseline by Week 16. In the dupilumab q2w group, 
mild incremental increases were observed through Week 
16. The median values showed even less fluctuation, which, 
along with the large standard deviation of the means, sug-
gests that the mean changes observed were influenced by a 
small number of outliers. Fluctuations in eosinophil counts 
were clinically inconsequential in all patients. A small num-
ber of patients had increases in eosinophil count during the 
treatment period that were reported either as a TEAE (1 
dupilumab + TCS-treated patient) or as Grade 3 eosino-
philia (7 dupilumab + TCS-treated patients and 1 placebo + 
TCS-treated patient) at one or more time points in the study, 
but none had symptoms or evidence suggesting systemic 
relevance. The eosinophil counts declined after the Grade 
3 events for most of these patients, supporting the likeli-
hood that this was a benign transient phenomenon, similar to 
what has been reported for adolescents and adults [16, 17]. 
Four of these patients had atopic comorbidities, including 
one patient with a medical history of asthma and TEAEs of 
asthma and urticaria; however, no patients had symptoms 
or findings suggestive of a systemic vasculitis. Eosinophilic 
granulomatosis with polyangiitis is a rare type of vasculitis 
that can present with co-occurring asthma and peripheral 
eosinophilia, but is unlikely in the patient population in this 
clinical trial, since it more commonly presents in adults with 
Table 5  Shift from baseline: neutrophils (×  109/L)
Normal range: age 1–6 years, 1.5–8.5 ×  109/L; age 7–12 years, 1.8–8.0 ×  109/L
n total number of patients in the treatment group, n1 number of patients with evaluation level (low, normal, high) at visit, N2 number of patients 
with baseline status, q2w every 2 weeks, q4w every 4 weeks, TCS topical corticosteroid
Study week Evaluation 
n1/N2 (%)
Placebo + TCS  
(n = 120)
Dupilumab 300 mg q4w + TCS 
(n = 120)
Dupilumab 100/200 mg q2w + TCS 
(n = 122)
Baseline status
Low Normal High Low Normal High Low Normal High
4 Low 1/7 (14.3) 1/101 (1.0) 0/3 2/5 (40.0) 2/102 (2.0) 0/1 3/8 (37.5) 2/100 (2.0) 0/2
Normal 6/7 (85.7) 97/101 (96.0) 3/3 (100) 3/5 (60.0) 96/102 (94.1) 1/1 (100) 4/8 (50.0) 94/100 (94.0) 2/2 (100)
High 0/7 3/101 (3.0) 0/3 0/5 4/102 (3.9) 0/1 1/8 (12.5) 4/100 (4.0) 0/2
8 Low 2/7 (28.6) 1/99 (1.0) 0/3 1/4 (25.0) 1/101 (1.0) 0/1 5/7 (71.4) 3/97 (3.1) 0/1
Normal 5/7 (71.4) 94/99 (94.9) 1/3 (33.3) 3/4 (75.0) 99/101 (98.0) 1/1 (100) 2/7 (28.6) 89/97 (91.8) 1/1 (100)
High 0/7 4/99 (4.0) 2/3 (66.7) 0/4 1/101 (1.0) 0/1 0/7 5/97 (5.2) 0/1
16 Low 1/5 (20.0) 4/98 (4.1) 0/3 3/4 (75.0) 12/108 (11.1) 0/1 5/8 (62.5) 2/104 (1.9) 0/2
Normal 4/5 (80.0) 90/98 (91.8) 3/3 (100) 1/4 (25.0) 93/108 (86.1) 1/1 (100) 3/8 (37.5) 102/104 (98.1) 1/2 (50.0)










Fig. 2  Mean change from baseline over time in serum levels of a LDH, b ALP, and c ALT. ALP alkaline phosphatase, ALT alanine aminotransferase, LDH lactate dehydrogenase, n1 number of 
patients at visit, q2w every 2 weeks, q4w every 4 weeks, SD standard deviation, TCS topical corticosteroid. aNumber of patients with a value for change from baseline
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severe asthma rather than in children with AD [28, 29]. No 
clinically relevant events or untoward outcomes were asso-
ciated with eosinophilia. Dual blockade of IL-4 and IL-13 
with dupilumab inhibits the activity of eosinophils and their 
recruitment to affected tissue, but not their egress from bone 
marrow (which is regulated by IL-5) [30–33]. It has been 
hypothesized that this may result in a transient increase in 
circulating eosinophils that does not reflect a pathologic pro-
cess [16, 17, 30].
There were no clinically meaningful differences observed 
in most serum chemistry parameters, and no clinically mean-
ingful differences were observed in urinalysis parameters 
among the treatment groups.
A reduction from baseline in mean LDH levels was 
observed in both dupilumab + TCS groups but not in the pla-
cebo + TCS group, similar to what was seen in dupilumab-
treated adults and adolescents with moderate-to-severe AD 
[16, 17]. Elevation in LDH is associated with inflammation 
and tissue damage and has been shown to decrease with 
improvements in clinical disease severity in patients with 
AD [34]. As noted above, the decline in platelet and neutro-
phil counts from baseline in the dupilumab + TCS groups 
may reflect the same process, as platelets and neutrophils are 
acute phase reactants associated with AD severity [21, 22].
Mild increases in mean ALP levels were observed in both 
dupilumab + TCS groups, whereas ALP levels remained 
relatively unchanged in the placebo + TCS group, similar 
to what was reported in adolescents [17]; however, no such 
increases were observed in adults [16]. As with the other 
age groups, there was no corresponding change in other liver 
function tests, and no corresponding change in parameters 
related to metabolic function, electrolytes, renal function, 
or lipids.
5  Limitations
This 16-week study was too short to assess long-term safety. 
An ongoing open-label extension study will provide more 
information on the long-term safety profile of dupilumab in 
children. Since exclusion criteria disallowed patients with 
evidence of liver disease (including persistent or elevated 
ALT or AST) or certain other severe laboratory abnormali-
ties, evaluation of patients with these morbidities was not 
performed. Potential irregularities in handling/processing of 
samples may not have been fully captured; thus, for example, 
laboratory artifacts such as pseudothrombocytopenia and 
hemolysis/potassium may have resulted from such irregu-
larities, but the data do not permit determination of such 
events. Biomarkers (such as IgE and thymus and activation-
regulated chemokine) and anti-dupilumab antibodies were 
assessed in this cohort; future publications are planned to 
report these parameters.
6  Conclusions
Treatment with dupilumab + TCS in children aged 6–11 
years with severe AD was not associated with clinically 
meaningful adverse changes in routine laboratory param-
eters. Dupilumab + TCS-associated decreases in platelet 
counts and LDH were similar to those reported in adoles-
cents and may represent improvements in AD-associated 
inflammation. These findings are consistent with outcomes 
previously reported in adolescents and adults with moderate-
to-severe AD [16, 17], support the pivotal efficacy and safety 
data previously reported for this clinical trial [15], and echo 
the observed trends in minor laboratory differences seen in 
adolescents and adults treated with this biologic agent [16, 
17]. Together with the results of previous studies in adults 
and adolescents, these data provide support that dupilumab 
does not require routine laboratory monitoring before initia-
tion or during treatment in children aged 6–11 years with 
severe AD.
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